GGrantIndex
← Leaderboards

Michelle Ng Gong

Massachusetts General Hospital

$11,453,323
Attributed
$19,088,166
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.4M · FY200520
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$17,895,133 · 9
AHRQ$1,193,033 · 1

By mechanism

U01$8,869,220 · 3
R01$4,267,744 · 2
UH3$3,271,943 · 1
R18$1,193,033 · 1
K23$649,755 · 1
UH2$611,559 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Critical Care

Research focus

Critical CareAcuteIntensive Care UnitsAdult Respiratory Distress SyndromeCritical IllnessPreventionLung InjuryInjuryPreventRandomized Controlled TrialsCaringMedicineHospitalsResearch InfrastructureOrgan FailureMultidisciplinaryClinical TrialsHigh RiskEnrollmentAdultClinical ResearchCostAccident And Emergency DepartmentComputerized Medical Record

Grant awards (40)

TREAT ECARDS: Translating Evidence into Action: Electronic Clinical Decision Support in ARDS$397,809
R18 · FY2020 · HS · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$336,753
U01 · FY2020 · HL · contact PI
Digital Implementation Intervention Trials in Acute Lung Care (DIGITAL-C) Network Planning$419,854
U01 · FY2019 · HL
TREAT ECARDS: Translating Evidence into Action: Electronic Clinical Decision Support in ARDS$397,898
R18 · FY2019 · HS · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$336,753
U01 · FY2019 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$653,512
UH3 · FY2018 · HL · contact PI
Digital Implementation Intervention Trials in Acute Lung Care (DIGITAL-C) Network Planning$456,989
U01 · FY2018 · HL
TREAT ECARDS: Translating Evidence into Action: Electronic Clinical Decision Support in ARDS$397,326
R18 · FY2018 · HS · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$234,848
U01 · FY2018 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$167,115
UH3 · FY2018 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$44,200
U01 · FY2018 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$820,627
UH3 · FY2017 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$277,188
U01 · FY2017 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$821,506
UH3 · FY2016 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$275,518
U01 · FY2016 · HL · contact PI
Utilizing Innovative Technology To Improve Compliance With Patient Elevation Guidelines – The Impact Of Angulus On Adherence To The Evidence-Based VAP-Prevention Bundle$224,912
R43 · FY2016 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$457,591
UH3 · FY2015 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$351,592
UH3 · FY2015 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$267,298
U01 · FY2015 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$8,611
U01 · FY2015 · HL · contact PI
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$611,559
UH2 · FY2014 · HL · contact PI
Einstein PETAL: Clinical Center for the PETAL Network$144,236
U01 · FY2014 · HL · contact PI
LIPS-A: Lung Injury Prevention Study with Aspirin$2,217,606
U01 · FY2013 · HL
LIPS-A: Lung Injury Prevention Study with Aspirin$2,384,003
U01 · FY2012 · HL
LIPS-A: Lung Injury Prevention Study with Aspirin$1,465,363
U01 · FY2011 · HL
Early Insulin Therapy and Development of ARDS$386,117
R01 · FY2011 · HL · contact PI
Early Insulin Therapy and Development of ARDS$417,188
R01 · FY2010 · HL · contact PI
Surrogate Consent in Research$402,965
R01 · FY2010 · HL · contact PI
Early Insulin Therapy and Development of ARDS$464,295
R01 · FY2009 · HL · contact PI
Surrogate Consent in Research$411,461
R01 · FY2009 · HL · contact PI
Early Insulin Therapy and Development of ARDS$454,040
R01 · FY2008 · HL · contact PI
Surrogate Consent in Research$411,461
R01 · FY2008 · HL · contact PI
Early Insulin Therapy and Development of ARDS$489,176
R01 · FY2007 · HL · contact PI
Surrogate Consent in Research$411,461
R01 · FY2007 · HL · contact PI
Surrogate Consent in Research$419,580
R01 · FY2006 · HL · contact PI
Molecular Epidemiology of ARDS and Septic Shock$129,951
K23 · FY2005 · HL
Molecular Epidemiology of ARDS and Septic Shock$129,951
K23 · FY2004 · HL
Molecular Epidemiology of ARDS and Septic Shock$129,951
K23 · FY2003 · HL
Molecular Epidemiology of ARDS and Septic Shock$129,951
K23 · FY2002 · HL
Molecular Epidemiology of ARDS and Septic Shock$129,951
K23 · FY2001 · HL